| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $44.32 | $44,320.00 | -100% | |
| May 1, 2018 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 126,832 | $80.75 | $10,241,734.73 | -26.8% | |
| May 1, 2018 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 4,510 | $18.04 | $81,369.70 | -2.4% | |
| May 1, 2018 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 50,000 | $44.02 | $2,201,166.53 | -3.6% | |
| Apr 30, 2018 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 8,801 | $18.00 | $158,457.00 | -3.0% | |
| Apr 26, 2018 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 4,194 | $18.00 | $75,492.00 | -3.9% | |
| Apr 25, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 180,000 | $80.85 | $14,553,614.20 | - | |
| Apr 25, 2018 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 163 | $13.85 | $2,257.55 | -0.2% | |
| Apr 23, 2018 | NVS Novartis AG | Novartis Institutes For Biomedical Research, Inc. | 10% Owner | Buy | 766,666 | $15.00 | $11,499,990.00 | +24.1% | |
| Apr 20, 2018 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 4,631 | $13.88 | $64,255.64 | -3.3% | |
| Apr 19, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Chairman, President And CEO | Sell | 44,400 | $26.00 | $1,154,401.00 | -3.9% | |
| Apr 19, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Vaughn Victor | Sr. VP Of Sales &Marketing | Sell | 17,850 | $47.93 | $855,471.89 | -48.9% | |
| Apr 18, 2018 | ANIP Ani Pharmaceuticals Inc | Marshbanks Tracy | Director | Sell | 33,200 | $62.09 | $2,061,388.00 | -6.9% | |
| Apr 18, 2018 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 13,450 | $13.93 | $187,325.68 | -7.8% | |
| Apr 17, 2018 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 7,893 | $55.00 | $434,115.00 | -25.2% | |
| Apr 16, 2018 | MRK Merck & Co., Inc. | Graddick Weir Mirian M | Exe V-p, Hr | Sell | 24,000 | $58.00 | $1,392,000.00 | -23.0% | |
| Apr 16, 2018 | LLY Eli Lilly & Co | Mahony Susan | SVP &Pres., Lilly Oncology | Sell | 22,544 | $80.09 | $1,805,633.42 | -23.4% | |
| Apr 6, 2018 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 2,517 | $14.02 | $35,288.34 | -2.8% | |
| Apr 5, 2018 | SUPN Supernus Pharmaceuticals, Inc. | Vaughn Victor | Sr. VP Of Sales And Marketing | Sell | 60,000 | $45.33 | $2,719,770.00 | -68.2% | |
| Apr 3, 2018 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | See Remarks | Sell | 27,313 | $15.30 | $417,897.09 | -14.3% | |
| Apr 3, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 26,942 | $2.90 | $78,072.14 | -32.5% | |
| Apr 2, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $46.75 | $46,750.00 | -100% | |
| Mar 29, 2018 | ESPR Esperion Therapeutics, Inc. | Newton Roger S | Director | Sell | 25,000 | $72.37 | $1,809,276.80 | -1.0% | |
| Mar 29, 2018 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 6,000 | $1.36 | $8,160.00 | +6.3% | |
| Mar 25, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 2,600 | $45.09 | $117,239.00 | -1.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.